Speaker at Global Conference on Pharmaceutics and Drug Delivery Systems 2018 - Lourdes Amable Vega Rasgado
Escuela Nacional de Ciencias Biologicas del Instituto Politecnico Nacional, Mexico
Title : EAAT3 proteins as a pharmacological target for the design of new antiepileptic drugs


people suffer from epilepsy, and 30% of them do not respond with traditional antiepileptic drugs. Thus, different strategies for seizures control in such patients are required. Seizures are the result of an imbalance between excitatory and inhibitory impulses on the central nervous system, being glutamate (GLU) the major excitatory neurotransmitter. GLU participates in several physiological but also pathological processes, including epilepsy. For recycling, to avoid neurotoxicity of ammonium generated during its metabolism and to finish its excitatory effect as neurotransmitter, GLU is removed from the synaptic cleft to the glia and back to neurons by GLU transporters, a family of proteins called EAATs. In neurons EAAT3 is highly expressed, which dysfunction has been implicated in epilepsy. EAATs activity is regulated by external GLU levels, and coupling GLU transportation by EAATs with the activity of enzymes related to its metabolism would improve the efficiency of the process. Here we study EAAT3 as a mechanism to counteract glutamatergic overstimulation that occurs in seizures.

Audience take away:
• Clarify a little bit more the roll of EAAT3 in seizures mechanism.
• To explore the coupling of GLU transportation through EAAT3 with its oxidative deamination.  
• Study the possibility of controlling seizures through modulations of EAAT3 activity.
• Evaluate the possibility of EAAT3 as a pharmacological target for the development of new antiepileptic drugs. 


Amable Vegavrasgado born on Mexico City, Mexico. Graduated as chemist, bacteriologist and parasitologist by Escuela Nacional de Ciencias Biológicas (ENCB) of Instituto Politécnico Nacional (IPN) México, with  master,s degree on pharmacology by Escuela Superior de Medicina of IPN. Master,s degree and PHD on neurosciences by Universidad de Salamanca, Spain. Professor of general and clinical biochemistry; head of clinical biochemistry academy and of neucrochemistry laboratory at biochemistry department from ENCB of IPN. Author of papers on different journals of neurobiochemistry and neuropharmacology. Main research lines: Alterations of brain biochemistry associated with epilepsy, schizophrenia, Parkinson,s and Alzheimer,s diseases; new drugs and diagnostic methods design.